These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1932836)

  • 1. [Breast cancer: can tamoxifen, under certain conditions, have adverse effects?].
    Cosset JM; Burtin P
    Bull Cancer; 1991; 78(8):685-6. PubMed ID: 1932836
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen and ocular toxicity.
    Ah-Song R; Sasco AJ
    Cancer Detect Prev; 1997; 21(6):522-31. PubMed ID: 9398992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tamoxifen controversy.
    Crabbe WW
    Oncol Nurs Forum; 1996 Jun; 23(5):761-6. PubMed ID: 8792346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.
    Sinawat S; Chiyabutra T; Kleabkaew P
    J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of tamoxifen on the female genital tract.
    Senkus-Konefka E; Konefka T; Jassem J
    Cancer Treat Rev; 2004 May; 30(3):291-301. PubMed ID: 15059652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer.
    Shenoy DB; Amiji MM
    Int J Pharm; 2005 Apr; 293(1-2):261-70. PubMed ID: 15778064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Postmenopausal hemorrhage and endometrial cancer in tamoxifen therapy].
    Krause A; Gerber B
    Zentralbl Gynakol; 1994; 116(1):44-7. PubMed ID: 8147180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of tamoxifen therapy on endometrium in breast cancer patients].
    Jiang SS; Tao RF
    Zhonghua Fu Chan Ke Za Zhi; 1995 Jan; 30(1):53-5. PubMed ID: 7750409
    [No Abstract]   [Full Text] [Related]  

  • 10. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female. A case report and review of the literature.
    Abudu EK; Musa O; Adefuye PO; Abdul Kareem FB; Agboola AO; Banjo AA
    Niger Postgrad Med J; 2007 Dec; 14(4):355-7. PubMed ID: 18163149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P; Vergote I
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ask the doctor. I've been taking tamoxifen for several months after completing treatment for breast cancer. My doctor prescribed it primarily to lower my risk of developing cancer in my unaffected breast. As a result of chemotherapy, I underwent menopause abruptly. Tamoxifen has worsened my symptoms, especially hot flashes and vaginal dryness. Other than stopping the tamoxifen, are there ways to deal with the side effects?
    Nicholson CR
    Harv Womens Health Watch; 1999 May; 6(9):8. PubMed ID: 10198465
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer.
    Köchli OR; Sevin BU; Averette HE; Haller U
    Contrib Gynecol Obstet; 1994; 19():12-23. PubMed ID: 7995043
    [No Abstract]   [Full Text] [Related]  

  • 15. Tamoxifen and breast cancer--from palliation to prevention.
    Rich SE
    Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
    Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
    Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
    Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
    Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How long should adjuvant tamoxifen be continued?
    Tripathy D
    Oncology (Williston Park); 1994 Oct; 8(10):25-33; discussion 33, 37-8. PubMed ID: 7803214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical adverse effects of chemoprevention: the example of tamoxifen].
    Sasco AJ; Ah-Song R; Saez S; Kuttenn F
    Bull Cancer; 1995 Jul; 82 Suppl 3():186s-206s. PubMed ID: 7492833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of post-chemotherapy tamoxifen in early breast cancer.
    Tolcher AW
    Oncology (Williston Park); 1994 Nov; 8(11):39-43; discussion 47-9. PubMed ID: 7826838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.